Business
PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting advancement toward IND submissionTEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of O
About this update from Prf Technologies Ltd.
[{"type":"image","alt":"PainReform Ltd","displaySize":"","headline":null,"caption":"PainReform Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":283,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8rnf4Sfc87De6ZQ.vLH_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a","width":283,"height":122}},"lazy":false},{"type":"text","content":"Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting advancement toward IND submission","length":151,"tagName":"p"},{"type":"text","content":"TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of OcuRing™-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery.","length":451,"tagName":"p"},{"type":"text","content":"The development program included a series of preclinical rabbit studies evaluating ocular tolerability, biocompatibility, and tissue response, as well as a Phase I clinical study in patients undergoing cataract surgery. Collectively, these studies demonstrated a favorable safety profile for the platform, supporting its advancement toward later-stage development.","length":364,"tagName":"p"},{"type":"text","content":"In the Phase I clinical study, no treatment-emergent adverse events related to the study drug were observed. All reported adverse events were as expected in the context of cataract surgery, and consistent with subjects’ underlying ocular histories. No serious adverse events were reported, and no safety issues related to the drug delivery platform were identified. The investigational product and intraocular lens devices remained properly positioned in all treated eyes throughout the study.","length":493,"tagName":"p"},{"type":"text","content":"Preclinical rabbit studies, similarly, demonstrated favorable local tolerability, with no evidence of ocular tissue abnormalities and no meaningful differences observe...